Michael Zasloff, MD, PhD
Founder, Chairman and CEO
Professor of Pediatrics and Genetics, Georgetown University, Dean of Research and Translational Science at Georgetown University, founder of Magainin and former President Magainin Research Institute
Over the past 25 years, Dr. Zasloff’s scientific interests have centered on the innate immune systems of animals. Dr. Zasloff received his M.D.-Ph.D. in the Medical Scientist Training Program at New York University School of Medicine. In the 1980’s, Dr. Zasloff was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, at the National Institutes of Health. In 1988 Dr Zasloff founded Magainin Pharmaceuticals, Inc. a publicly traded biotechnology company. In the same year he joined the faculty of the University of Pennsylvania School of Medicine as the Charles E. H. Upham Professor of Pediatrics and Genetics, and assumed the position of Director of the Division of Human Genetics of the Children’s Hospital of Philadelphia. In July 1992 Dr. Zasloff left Penn and joined Magainin on a full time basis, and served as Executive Vice President and President of the Magainin Research Institute, a basic research division of the Company. From July 1996 through November 2000 Dr. Zasloff was Vice Chairman of the Board of Magainin Pharmaceuticals. In 2002, Dr. Zasloff was named Dean of Research and Translational Science at Georgetown, tasked with the integration of the basic science conducted at Georgetown with the clinical environment of the Medical Center. Between 2004 and 2006 Dr. Zasloff also served as Senior Vice President for Biotechnology for Ferris, Baker Watts, and an investment firm in D.C.
Since 2004, Dr. Zasloff has been actively engaged in studies of innate immunity as Scientific Director of the MedStar-Georgetown Transplant Institute. His research interests remain focused on the role of antimicrobial peptides and aminosterols in health and disease, and application to the prevention and treatment of disease. He has published over 150 peer reviewed articles, and holds over 40 issued US patents.
He recently founded Enterin, Inc. where he serves as Chairman and CEO. He also serves as the lead independent Director on the Board of Amphastar Pharmaceuticals, Inc. and is a Director at Sarentis Therapeutics and Novo Therapeutics. He has received numerous awards including an honorary Doctor of Science from Georgetown University in 2011.
Denise Barbut, MD, FRCP
Co-founder, President and Chief Medical Officer
Professor of Neurology & Former Chief of Neurovascular Division at Weill-Cornell Medical College. Founder, Chair, and CEO of several med-tech and biotech companies. Holder of close to 200 patents.
Dr. Barbut was brought up in Istanbul, Turkey. She trained as an internist and subsequently as a neurologist in Great Britain and the USA. She received her bachelor’s degree from University College London and her Medical Degree from University College Hospital. She did her post-graduate training at Imperial College, the Royal Brompton Hospital and the National Hospital for Neurology and Neurosurgery, Queens’ Square. She is a Fellow of the Royal College of Physicians of the United Kingdom. She completed her neurologic training at Weill-Cornell Medical Center- Cornell University Medical College and Memorial Sloan-Kettering Cancer Center. Subsequently she became an Attending Physician at New York Hospital and Professor of Neurology at Cornell University. She was Chief of the Neurovascular Division and of the Stroke Research Program.
She left academia in 2000 after founding the second of her 5 companies. Dr. Barbut is sole author or lead author on close to 200 issued or pending patents, mostly relating to methods for neuroprotection, cerebral hypothermia, the treatment of cerebral ischemia, pain, neuromodulation, Parkinson’s disease and other neurodegenerative disorders. She is also the lead or senior author on over 100 peer-reviewed articles and abstracts. She has been involved in founding, funding and running biotech companies for 20 years.
She recently co-founded Enterin, where she serves as President and CMO. She is also Board Chair at Novo Therapeutics, Sarentis Therapeutics and Muse and Board member at Israel Brain Technologies.
William Kinney, PhD
Co-Founder, Senior VP, Research & Development
Dr. Kinney is a drug discovery scientist, process development chemist, and entrepreneur with greater than 30 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development.
He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, natural products, and cGMP drug development; and is inventor of three molecules that advanced to human clinical trials – Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity). He was the chemistry leader on the initial squalamine IND project team, delivering drug substance to launch a Phase I clinical trial on time and on budget. The squalamine cGMP scale-up campaign required building and leading an internal process group, partnering with analytical chemistry on method development and stability studies, working with multiple domestic and international collaborators, and writing the CMC section of the IND.
In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications. He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.
Currently, Dr. Kinney is co-founder and Vice President of Research and Development at Enterin, Inc. where he leads scale-up of drug substance and drug product for the ENT-01 IND for the treatment of Parkinson’s Disease. His scientific contributions include 80 publications, invited lectures, and oral presentations and inventorship on 42 issued U.S. patents.
Barbara Carlin, CPA, MBA
Chief Financial Officer
Barbara Carlin joined Enterin as Chief Financial Officer in May 2019. Ms. Carlin has over 20 years of experience providing financial and operational leadership in public and privately held companies with a focus on the emerging growth life sciences community. Prior to joining Enterin, Ms. Carlin served as Senior Vice President and Chief Accounting Officer of Egalet Corporation, a biopharmaceutical company focused on developing and commercializing products for pain and inflammation. At Egalet, Ms. Carlin built the financial infrastructure after its IPO in 2014. During her tenure, she served on the leadership team through corporate reorganization and multiple debt and equity financings and led the financial integration of multiple product acquisitions, in-licensing arrangements and commercial product launches.
She has held financial leadership positions in life science companies including Sobi, Topaz Pharmaceuticals, moksha8 Pharmaceuticals, Genaera Corporation and Vicuron Pharmaceuticals. She also served in various roles in finance and accounting at public companies in the professional services and publishing space. Ms. Carlin started her career in accounting at Deloitte and Touche LLP. She earned her bachelor’s degree in accounting and a Master’s Degree in Healthcare and Pharmaceutical Business from St. Joseph’s University in Philadelphia, PA. She is a certified public accountant licensed in the Commonwealth of Pennsylvania.
Brian Harvey, MD, PhD
Senior VP, Global Regulatory Affairs
Dr. Harvey is a physician and biochemist with academic research, clinical practice, U.S. FDA regulatory, bio-pharmaceutical industry and non-profit experience. Dr. Harvey has held positions as Vice President of U.S. Regulatory Strategy at Pfizer and Vice President of U.S. Regulatory Policy at Sanofi-Aventis.
Dr. Harvey also held several senior roles at FDA, serving in the medical device (CDRH), biologic (CBER) and drug (CDER) centers from 1995 to 2007. As Director, he created the Inborn Errors of Metabolism Team within the GI Division to focus on rare disease product approvals. Prior to this, he served as Deputy Director for the Office of Drug Evaluation 5 (CDER) and CBER Associate Director for Policy, Office of Therapeutics Research and Review (OTRR).
Dr. Harvey graduated with honors from Middlebury College in Vermont. After college, he received his PhD in biochemistry, followed by his MD at the University of Connecticut. He completed his internship and residency in internal medicine at Harvard’s Beth Israel Hospital. This was followed by a three year gastroenterology fellowship at Johns Hopkins Hospital, Baltimore.